Van had RIOT at $1-$9 saying it would hit $30 when nobody here thought that possible because he saw Bitcoin potential. I wish I had his ability to see the potential big picture moves. It hit $79 today, that’s why Van and Stoney are stock picking gods!
Aaaaaaaa.... I wish you would have held off a tad. It'll test the low 17's again. That's just the way these things play out. Well, if it breaks north out of the gate tomorrow, dump it. There'll be plenty of time to get in later. If it keeps heading up, well, there's no crime in buying high. This is a new one. Ya gotta be careful. I like it, but they get choppy when they first come out.
No its not.... But don't tell Mrs Stoney. https://www.operaandballet.com/peop...ate_from=05-Apr-2017&play_date_to=09-Apr-2017
don't worry! (though i understand worrying over things). i'm a satisfied GHVI stock owner. it's up two points already and i promise to sell if i feel it moving down...
Good Morning. This pot stock has caught my eye a few times I don't know why others don't use their business model -- they are a consolidator. Ayr Strategies tapped by Needham for 2021 tally Dec. 23, 2020 7:21 AM ETAYR Strategies Inc. (AYRWF) Needham keeps a Buy rating on Ayr Strategies(OTCQX:AYRWF)into 2021 as it factors in the company's recent acquisitionsin Florida and New Jersey. "AYR has an outstanding, but narrow, operating footprint at present, but with a feverish pace of M&A in recent months will see expansion into 5 new states. If integrated and operated to the standards set by Ayr assets in NV and MA, we expect these to be outstanding assets. That said, we would generously describe the FL asset as a 'fixer upper,' and note that growth in NJ is contingent upon facility expansion underway. Additionally, we point out that integration and execution risk increases with the number of markets being acquired." The firm notes that at a 7.5X EV/EBITDA multiple on its 2021 estimate, Ayr trades at 1/2 the multiple of peers. While execution risk is seen, Needham think the prospects for equity appreciation on growth and multiple re-rating are strong.
--Immunome discovers antibodies able to neutralize multiple SARS-CoV-2 variants 07:18 IMNM --NGM Biopharmaceuticals participates in a conference call with Cowen 17:37 NGM Biotechnology Analyst Baral holds a conference call with management on February 19 at 12 pm hosted by Cowen. --Ingevity names Jean Blackwell as Chair of the board 16:19 NGVT Ingevity announced that Jean Blackwell has been elected by the company's board of directors as chair of the board. Jean's appointment comes in the wake of the death of former Chairman Richard B. Kelson on February 13, 2021. Blackwell has been a member of Ingevity's board of directors since the company's spin-off from WestRock in 2016. She has served as the chair of the Audit Committee and a member of the Leadership Development and Compensation Committee. --Butterfly Network Inc (Class A Stock) call volume above normal and directionally bullish 15:45 BFLY Bullish option flow detected in Butterfly Network Inc (Class A Stock) with 33,502 calls trading, 5x expected, and implied vol increasing almost 9 points to 137.81%. Feb-21 25 calls and Feb-21 20 calls are the most active options, with total volume in those strikes near 11,800 contracts. The Put/Call Ratio is 0.08. --Immunic '838 remains 'solid call option' as COVID therapeutic, says Roth Capital 14:30 IMUX Roth Capital analyst Zegbeh Jallah notes that Immunic released results from the main analysis of its Phase 2 CALVID-1 study of IMU-838 in patients with moderate COVID-19. The primary endpoint of proportion of patients without need for invasive ventilation was not evaluable due to low event rate. Encouragingly, secondary-endpoints trended in the right direction, including time-to-clinical-recovery and time-to-improvement, Jallah adds. As the COVID opportunity was always a call-option in the analyst's model, Jallah views the selloff as overdone. The analyst has a Buy rating and $64 price target on the shares. --Antero Midstream reports Q4 adjusted EPS 21c, consensus 20c 16:39 AM Reports Q4 revenue $239.07M, consensus $197.56M. Paul Rady, Chairman and CEO said, "In a separate release, Antero Resources announced the formation of a drilling partnership through 2024 that is expected to result in incremental throughput and fresh water volume growth on Antero Midstream dedicated acreage. As a result, Antero Midstream is forecasting a 2021 capital budget of $240 to $260 million, reflecting approximately $65 million of incremental capital that has been accelerated into 2021 above the previous maintenance capital program. To fund this acceleration, Antero Midstream expects to reallocate a portion of its dividend payments to fund the associated infrastructure projects supporting the increased volumes and water usage anticipated due to the drilling partnership. This reallocation is expected to allow Antero Midstream to internally fund these attractive rate of return projects without adding leverage or total debt."
--Corvus Pharmaceuticals Chairman Miller buys 100K shares of company stock 17:05 CRVS Corvus Pharmaceuticals Chairman Richard Miller disclosed that he had purchased 100,000 shares of stock at $3.50 per share on February 17 for a transaction amount of $350,000. --Pfizer, BioNtech say NEJM publishes data on sera 17:15 PFE, BNTX Pfizer (PFE) and BioNTech (BNTX) announced results from an in vitro study that provides additional data on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vaccine to neutralize SARS-CoV-2 with the South African variant spike protein. This study, which builds on previous work, was conducted by Pfizer and the University of Texas Medical Branch, and results were published in the New England Journal of Medicine. The current in vitro study investigated the full set of South African variant (also known as B.1.351 lineage) spike mutations. To this aim, three genetically engineered recombinant viruses were produced. One virus had the full set of spike glycoprotein mutations found in the South African variant and the other two had subsets of these mutations. The viruses were tested against a panel of sera from 20 participants in the previously reported Phase 3 trial who had been immunized with the Pfizer-BioNTech COVID-19 vaccine. Although the results indicated a reduction in neutralization of virus with all the South African variant spike glycoprotein mutations, all the sera neutralized all the viruses tested. This finding is consistent with recent reports of the neutralization of variant SARS-CoV-2 or corresponding pseudoviruses by convalescent or post-immunization sera
Stoney... remember ELYS? The gaming company. The one you didn't like because the guy was Italian and I liked because he was buying his own stock like a maniac? Well it just hit one of my scanners. $8.27 now. https://www.elitetrader.com/et/threads/ideas-for-now.343946/page-276#post-5266949